Recombinant fowlpoxvirus expressing HIV gag-pol antigens vaccine(Virax Pty)(Recombinant fowlpoxvirus expressing HIV gag-pol antigens vaccine(Virax Pty))

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症-

非在研适应症

获得性免疫缺陷综合征

原研机构

Virax Pty. Ltd

在研机构-

非在研机构

Virax SA

最高研发阶段无进展临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Recombinant fowlpoxvirus expressing HIV gag-pol antigens vaccine(Virax Pty) 相关的临床试验

NCT00332930

/ Completed临床1/2期

An Extension Study to Protocol VIR-NCHR-01 to Assess the Antiretrovirological Properties of a Therapeutic HIV Vaccine Candidate Based on Recombinant Fowlpox Virus (rFPV) (ITV Extension Study)

The objective of this phase I/II therapeutic human immunodeficiency virus (HIV) vaccine candidate study is to provide proof of concept for a HIV antigen delivery system in terms of safety, virological effects and selected immune responses in HIV infected individuals after cessation of antiretroviral combination therapy (ART).

开始日期2002-09-01

申办/合作机构